logo
3 CD account mistakes savers should avoid making this July and August

3 CD account mistakes savers should avoid making this July and August

CBS News10-07-2025
To better protect their CD account, savers will need to know which timely mistakes to avoid making now.
witthaya_prasongsin/Getty Images
In recent years, savers could do no wrong by depositing money into a certificate of deposit (CD) account. With interest rates on these accounts multiple times higher than they were at the beginning of the decade and with those rates fixed, all savers needed to do was find an online bank to get started. By depositing the right amount of money into the right account, they could earn hundreds if not thousands of dollars with very little risk or effort.
But the economy is changing again, and thus, the CD landscape isn't quite what it was in 2023 or 2024. In today's climate, with multiple rate cuts already issued and additional ones predicted for later this summer, savers will need to be a bit more strategic in their approach. That doesn't mean that CD accounts should be avoided (rates here still comfortably sit over 4%). But it does mean that savers will need to be more nuanced in their approach.
That extends to knowing both what to do and what mistakes to avoid making this July and August, specifically. Below, we'll detail three CD account mistakes savers should be aware of right now.
See how high today's CD interest rates are online here.
3 CD account mistakes savers should avoid making this July and August
By understanding and avoiding these specific mistakes this summer, savers can better position themselves for CD account success:
Mistake: Assuming CD rates will only change when the Fed takes action
The chances of a rate cut at the Federal Reserve's July meeting are less than 7%, according to the CME Group's FedWatch tool. But they surged to almost 70% for the September meeting. So, yes, rate cuts are likely at some point this summer. Still, prospective CD account holders shouldn't just assume that rate changes will only take place when the central bank takes action.
Many banks will adjust their rates before the Fed does, perhaps to a significant degree and potentially sooner than expected. So it would be a mistake to pass on a high-rate CD account offer now, while still readily available. Don't think you have more time to shop around than you actually do. If you find a high-rate CD online today, there's a strong argument to be made for locking it in, as rate changes aren't easy to time or predict, especially right now.
Compare your current CD offers online and learn more.
Mistake: Getting distracted by higher, short-term CD rates
It's understandable if you want to earn the highest interest rate possible on your savings accounts while paying the lowest interest rate possible when borrowing. But you shouldn't let the interest rate distract you from your primary goal, which is to earn as much interest as you can, regardless of the time it takes to do so.
While short-term CD rates can be considerably higher than their long-term counterparts now (think around 25 basis points), those short-term rates will mature in less than a year, potentially leaving you with less attractive options at that point. Long-term CDs, however, will earn a high rate for an extended period of 18 months or longer, allowing you to both grow your principal and protect your money against rate cuts to come, neither of which a short-term CD can offer to the same degree right now.
Mistake: Not calculating the interest-earning potential before depositing money
The caveat with CD accounts is clear: You'll be required to leave your money in the account for the full term to earn the interest, or see it negated by an early withdrawal penalty. If you can't make that commitment, then an alternative like a high-yield savings account may be the better fit. The financial sacrifice required with a CD, however, can be easily determined by calculating the interest-earning potential in advance of any deposit. So don't make the mistake of avoiding this math now, especially with rate cuts looming. By completing these calculations, you'll be better able to determine if a CD is worth it for you now and, specifically, in which amount and for which term.
The bottom line
The value of a CD account has been especially strong in 2022 and beyond and even though rates here are diminishing, savers can still make an account an integral part of their savings plan. But they'll need to avoid making these three simple but easy mistakes right now. By understanding these errors and taking proactive action to avoid them, these CD account holders can position themselves for long-term success, despite any market changes on the horizon.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

What Makes Eli Lilly and Company (LLY) a Lucrative Investment?
What Makes Eli Lilly and Company (LLY) a Lucrative Investment?

Yahoo

time2 minutes ago

  • Yahoo

What Makes Eli Lilly and Company (LLY) a Lucrative Investment?

Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Eli Lilly and Company (NYSE:LLY). Eli Lilly and Company (NYSE:LLY) is a pharmaceutical company headquartered in Indianapolis, Indiana. The one-month return of Eli Lilly and Company (NYSE:LLY) was -2.64%, and its shares lost 5.52% of their value over the last 52 weeks. On July 30, 2025, Eli Lilly and Company (NYSE:LLY) stock closed at $760.08 per share, with a market capitalization of $682.351 billion. Baron Health Care Fund stated the following regarding Eli Lilly and Company (NYSE:LLY) in its second quarter 2025 investor letter: "We added to our position in Eli Lilly and Company (NYSE:LLY), a global pharmaceutical company best known for developing and selling GLP-1 medications for diabetes and obesity. The most recent generation of GLP-1 drugs (brand names Mounjaro and Zepbound) not only offer superb blood sugar control for diabetics, but also can drive 20% or greater weight loss and likely improve cardiovascular outcomes in both diabetic and non-diabetic obese patients. We think these drugs will become the standard of care for both diabetes and obesity, and will become a $150 billion category. We see Lilly as the leader in the space, setting a high efficacy bar with their GLP-1s on the market and continuing to innovate and develop next-generation medications that are more effective and more convenient. We are excited about once-daily oral orforglipron, which recently showed Phase 3 data in type 2 diabetes that rivaled Novo Nordisk's injectable Ozempic. We expect Phase 3 orforglipron in obesity this summer to also be competitive with Novo Nordisk's injectable Wegovy. Beyond orforglipron, Lilly is also studying a high efficacy injectable (retatrutide) in Phase 3, an amylin hormone analogue (eloralintide) that can be combined with Zepbound in Phase 2, and a muscle preserving drug bimagrumab (which can also be combined with Zepbound) in Phase 2. We continue to think this market is in the early innings of uptake, we think the adoption of GLP-1s will drive Lilly to triple its total revenues by 2030, and we think Lilly has the pipeline portfolio of drugs to sustain its leadership position." Eli Lilly and Company (NYSE:LLY) is in 21st position on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 119 hedge fund portfolios held Eli Lilly and Company (NYSE:LLY) at the end of the first quarter, which was 115 in the previous quarter. Eli Lilly and Company (NYSE:LLY) reported strong results in first quarter of 2025, with revenue increasing 45% compared to Q1 2024. While we acknowledge the potential of Eli Lilly and Company (NYSE:LLY) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Eli Lilly and Company (NYSE:LLY) and shared the list of stocks Jim Cramer recently discussed. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Excellent Execution Drove IDEXX Laboratories (IDXX) Shares Amid Macro Challenges
Excellent Execution Drove IDEXX Laboratories (IDXX) Shares Amid Macro Challenges

Yahoo

time2 minutes ago

  • Yahoo

Excellent Execution Drove IDEXX Laboratories (IDXX) Shares Amid Macro Challenges

Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as IDEXX Laboratories, Inc. (NASDAQ:IDXX). IDEXX Laboratories, Inc. (NASDAQ:IDXX) develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets. The one-month return of IDEXX Laboratories, Inc. (NASDAQ:IDXX) was 4.58%, and its shares gained 22.08% of their value over the last 52 weeks. On July 30, 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) stock closed at $572.09 per share, with a market capitalization of $46.009 billion. Baron Health Care Fund stated the following regarding IDEXX Laboratories, Inc. (NASDAQ:IDXX) in its second quarter 2025 investor letter: "Shares of veterinary diagnostics leader IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to performance for the quarter after reporting better than-expected financial results. Foot traffic to veterinary clinics in the U.S. remains under pressure, which has continued to hamper aggregate revenue growth. Despite macroeconomic challenges, IDEXX's excellent execution has enabled the company to maintain strong performance. We believe competitive trends are outstanding, and we expect new proprietary innovations and field sales force expansion to be meaningful contributors to growth in 2025. We see increasing evidence that long-term secular trends around pet ownership and pet care spending have structurally accelerated, which should help support IDEXX's long-term growth rate." A veterinarian in a veterinary clinic examining a companion animal. IDEXX Laboratories, Inc. (NASDAQ:IDXX) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 51 hedge fund portfolios held IDEXX Laboratories, Inc. (NASDAQ:IDXX) at the end of the first quarter, which was 58 in the previous quarter. In the first quarter of 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) reported organic revenue growth of 5% driven by 4.5% organic revenue gains in the CAG business, 7% organic growth in water, and 4% organic growth in LPD. While we acknowledge the potential of IDEXX Laboratories, Inc. (NASDAQ:IDXX) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered IDEXX Laboratories, Inc. (NASDAQ:IDXX) and shared the list of best stocks to buy according to Brasada Capital Management. In Q2 2025, IDEXX Laboratories, Inc. (NASDAQ:IDXX) contributed to Conestoga Capital Advisors' performance. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Baron Health Care Fund Reacquired Edwards Lifesciences Corporation (EW) in Q2. Here's Why
Baron Health Care Fund Reacquired Edwards Lifesciences Corporation (EW) in Q2. Here's Why

Yahoo

time2 minutes ago

  • Yahoo

Baron Health Care Fund Reacquired Edwards Lifesciences Corporation (EW) in Q2. Here's Why

Baron Funds, an investment management company, released its 'Baron Health Care Fund' second-quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund declined 5.06% (Institutional Shares) in the quarter, against a challenging backdrop for the broader Health Care sector, compared to a 6.19% decline for the Russell 3000 Health Care Index (benchmark) and a 10.99% gain for the Russell 3000 Index (the Index). In addition, please check the fund's top five holdings to know its best picks in 2025. In its second-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as Edwards Lifesciences Corporation (NYSE:EW). Edwards Lifesciences Corporation (NYSE:EW) offers products and technologies for structural heart disease and critical care monitoring. The one-month return of Edwards Lifesciences Corporation (NYSE:EW) was 5.69%, and its shares gained 31.20% of their value over the last 52 weeks. On July 30, 2025, Edwards Lifesciences Corporation (NYSE:EW) stock closed at $81.16 per share, with a market capitalization of $47.608 billion. Baron Health Care Fund stated the following regarding Edwards Lifesciences Corporation (NYSE:EW) in its second quarter 2025 investor letter: "We reacquired shares of Edwards Lifesciences Corporation (NYSE:EW), a leading manufacturer of heart valve replacement and repair products. Transcatheter aortic valve replacement (TAVR) is a minimally invasive procedure to treat aortic stenosis, a disease that obstructs the flow of blood out of the aortic valve, which strains the heart. Edwards Lifesciences has a leading position in the TAVR market backed by a robust body of clinical evidence and physician familiarity with the product and workflow. TAVR is a $5 billion market that still continues to grow many years after Edwards Lifesciences first entered the market. We expect this growth to continue at a moderate pace as indications expand to cover a broader patient population. In addition, competitor Boston Scientific Corporation recently exited the TAVR market, which provides incremental market share opportunity for Edwards Lifesciences. A skilled surgeon surrounded by a team of medical professionals performing a Transcatheter Heart Valve Replacement. Edwards Lifesciences Corporation (NYSE:EW) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 63 hedge fund portfolios held Edwards Lifesciences Corporation (NYSE:EW) at the end of the first quarter, which was 67 in the previous quarter. Edwards Lifesciences Corporation (NYSE: EW) reported total sales of $1.53 billion in Q2 2025, reflecting a growth of 10.6%, which exceeded expectations. While we acknowledge the potential of Edwards Lifesciences Corporation (NYSE:EW) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we discussed Edwards Lifesciences Corporation (NYSE:EW) and shared Jim Cramer's latest thoughts. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store